| Study Name |
Location |
Enrollment |
Design |
Purpose |
Primary Outcome(s) |
| DENER-HTN |
France |
April 2012 |
multi-center, open label RCT |
RD + conventional medical therapy v.
medical therapy alone |
Mean ambulatory BP, cost effectiveness |
| Renal Denervation in patients
with advanced heart failure |
Turkey |
April 2012 |
observational |
Test improvement in ventricular function
and functional capacity after RD in
advanced heart failure population |
Safety measured by MACE |
| Global SYMPLICITY registry |
Germany |
Feb 2012 |
open label, multi-center registry |
Document 5- year safety and efficacy
profile from minimum 5000 patients at
200 centers; data collection diabetes,
CHF, CKD |
Long-term BP measurements
after RD in relation to sympathetically
driven diseases |
| DREAMS |
Netherlands |
Nov 2011 |
observational |
Test efficacy of RD on insulin resistance
in metabolic syndrome |
Decrease in insulin resistance
after 12 months |
| Renal Denervation in patients
with chronic heart failure and
renal impairment |
Australia |
Oct 2011 |
observational |
Feasibility study of RD in heart failure
patients with renal dysfunction |
Safety measured by MACE |
| PRAGUE-15 |
Czech Republic |
Oct 2011 |
observational |
RD + conventional medical therapy v.
medical therapy alone (5 years) |
Decrease in office BP, MACE |
| SYMPLICITY HTN-3 |
United states |
Sept 2011 |
multi-center, single blind RCT |
Test efficacy and safety of RD in refractory
hypertension on a large scale |
Decrease in office BP after 6
months |
| ReSET |
Denmark |
Sept 2011 |
single-center, multi blind RCT |
Test efficacy of RD in improving ambulatory
blood pressure |
Ambulatory BP change at 3
months |
| Renal sympathetic modifications
in patients with metabolic
syndrome |
China |
Aug 2011 |
observational |
Measure effects of RD on cardiovascular
events , glucose and lipid
metabolism |
Composite MACE |
| Renal nerve ablation in chronic
kidney disease patients |
Germany |
Nov 2010 |
observational |
Evaluate and understand pathogenesis
of RD in the CKD population |
Ambulatory BP, renal perfusion
, Na+ excretion, RAS activity,
vascular structure and function |
| Combined treatment of resistant
hypertension and atrial
fibrillation |
Greece |
April 2010 |
observational |
RD + PVI v. PVI alone to reduce AF
recurrence |
BP lowering, freedom from AF |
RD: Renal Denervation